Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce H Mitlak

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Current Opinion in Pharmacology|December 17, 2002
Parathyroid hormone as a therapeutic agentBruce H Mitlak
Current Medical Research and Opinion|July 27, 2011
Long-term raloxifene for postmenopausal osteoporosisRobert R Recker, Bruce H Mitlak, Xiao Ni, et al.
Menopause (New York, N.Y.)|February 25, 2025
Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fractureKristi Tough DeSapri, Bart L Clarke, Paul Kostenuik, et al.
JBMR Plus|July 22, 2025
The effect of abaloparatide on the proximal femur in men with osteoporosis assessed by three-dimensional dual-energy X-ray absorptiometryRuban Dhaliwal, John Boxberger, Yamei Wang, et al.
Bone Reports|December 5, 2019
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendChad L Deal, Bruce H Mitlak, Yamei Wang, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 5, 2002
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapySomnath Sarkar, Bruce H Mitlak, Mayme Wong, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 11, 2003
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structureYebin Jiang, Jenny J Zhao, Bruce H Mitlak, et al.
Bone|October 22, 2011
Femoral strength in osteoporotic women treated with teriparatide or alendronateTony M Keaveny, Michael R McClung, Xiaohai Wan, et al.
The Journal of Bone and Joint Surgery. American Volume|June 3, 2009
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trialsMary L Bouxsein, Peiqi Chen, Emmett V Glass, et al.
The Journal of Bone and Joint Surgery. American Volume|April 5, 2005
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)Yaser M Alkhiary, Louis C Gerstenfeld, Elizabeth Krall, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Opinion in Pharmacology|December 17, 2002
Parathyroid hormone as a therapeutic agentBruce H Mitlak
Current Medical Research and Opinion|July 27, 2011
Long-term raloxifene for postmenopausal osteoporosisRobert R Recker, Bruce H Mitlak, Xiao Ni, et al.
Menopause (New York, N.Y.)|February 25, 2025
Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fractureKristi Tough DeSapri, Bart L Clarke, Paul Kostenuik, et al.
JBMR Plus|July 22, 2025
The effect of abaloparatide on the proximal femur in men with osteoporosis assessed by three-dimensional dual-energy X-ray absorptiometryRuban Dhaliwal, John Boxberger, Yamei Wang, et al.
Bone Reports|December 5, 2019
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendChad L Deal, Bruce H Mitlak, Yamei Wang, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 5, 2002
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapySomnath Sarkar, Bruce H Mitlak, Mayme Wong, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 11, 2003
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structureYebin Jiang, Jenny J Zhao, Bruce H Mitlak, et al.
Bone|October 22, 2011
Femoral strength in osteoporotic women treated with teriparatide or alendronateTony M Keaveny, Michael R McClung, Xiaohai Wan, et al.
The Journal of Bone and Joint Surgery. American Volume|June 3, 2009
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trialsMary L Bouxsein, Peiqi Chen, Emmett V Glass, et al.
The Journal of Bone and Joint Surgery. American Volume|April 5, 2005
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)Yaser M Alkhiary, Louis C Gerstenfeld, Elizabeth Krall, et al.
Pageof 3